A total of 36 patients were enrolled on the study, including 20 who received zilurgisertib monotherapy (group A) and 16 who received zilurgisertib plus a stable dose of ruxolitinib (group B), Bose explains. The open-label, phase 1/2 INCB 00928-104 study (NCT04455841) evaluated the selective ALK-2 inhibitor zilurgisertib in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis. Inhibition of ALK-2may combat hepcidin overexpression, making it a potential target for anemia management. This has been associated with poorer prognosis. Patients with myelofibrosis will often experience anemia due to dysregulation of the iron regulator hepcidin. Prithviraj Bose, MD, associate professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses key data on the use of zilurgisertib alone or in combination with ruxolitinib (Jakafi) to reduce disease-related anemia in patients with primary or secondary myelofibrosis. Prithviraj Bose, MD, discusses key data on the use of zilurgisertib alone or in combination with ruxolitinib to reduce disease-related anemia in patients with primary or secondary myelofibrosis. This is not enough to cover its annual cash burn of $ Bose on the Use of Zilurgisertib With/Without Ruxolitinib to Reduce Anemia in Myelofibrosis BPMC has $827.37M in cash and short term investments.BPMC profit margin has gone up by 0.1 percentage points in the past year, but the company is still unprofitable.BPMC has a relatively high debt to equity ratio of 1.95.Total BPMC debt is higher than 5 years ago, relative to shareholder equity.It has sufficient cash and short-term investments to cover this for at least one year. There are more short-term assets than short-term liabilities on the BPMC balance sheet.There are more short-term assets than long-term liabilities on the BPMC balance sheet.You can access more valuation analysis on BPMC's stock here. BPMC could be overvalued based on its P/B ratio of 8.95x, relative to Biotechnology industry P/B ratio of 5.3x.Investors use a variety of different financial metrics, analyses, models, and charts to gauge BPMC's fair value. You can see all of the due diligence checks on BPMC's stock page. WallStreetZen was built to help part-time investors do more in-depth fundamental analysis in less time. Keep an eye on your investment in BPMC: Create a watchlist to important updates regarding your new investment in Blueprint Medicines stock. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |